Skip to main content
Equibles
BJDX logo

BJDX · Bluejay Diagnostics, Inc. · Metrics

Track BJDX — free

Use BJDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BJDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.84 -0.01 (-1.12%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These financial results and financial position, and the Company’s expected forward-looking outlook of significant negative cash flow in the future, raise substantial doubt with respect to its ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$4.20M
Shares
4.47M
Volume · Oct 2 114.84K Avg daily vol (3M) 5.57M

BJDX metrics

47 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.84
Market cap
$4.20M

Price action

20 metrics
Price change (1W)
-9.2%
Price change (30D)
+0.6%
Price change (3M)
-26.6%
Price change (6M)
-57.1%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
176.0%
Annualized volatility (3M)
126.7%
Beta
1.2
RSI (14D)
40.7
Price vs SMA 50
-11.7%
Price vs SMA 200
—
Avg volume (3M)
5.57M
Relative volume
0.0
Average dollar volume
$6.84M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
4.47M

Valuation

12 metrics
P / E (TTM)
1.1
Trailing earnings · reciprocal yield 93.2%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.4
reciprocal yield 224.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-173.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
19.6%
Operating margin
-3,741.5%
Trailing 12 months
Net margin
-3,733.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$7.37M
Net income (TTM)
−$7.27M
Trailing 12 months
Diluted EPS (TTM)
$0.78
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$39.54

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+499.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-77.2%
Return on assets
-63.0%
Debt / equity
—
Current ratio
4.6
EBITDA (TTM)
−$9.16M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9.60M
Latest balance sheet
Cash & equivalents
$9.60M
Total assets
$11.53M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.90M
Capital expenditures (TTM)
—
R&D (TTM)
$3.62M
SG&A (TTM)
$141,821
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
8
13F filer change QoQ
+2
Institutional ownership
4.8%

Short interest

3 metrics
Short interest
2.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
36 / 100

Insider activity

2 metrics
Net insider buying (90D)
$47,798
Insider-sentiment score
78 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1704287 CUSIP 095633608 Visit website Investor relations